NCT02329834View on ClinicalTrials.gov

Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

23

Participants

Timeline

Start Date

April 30, 2015

Primary Completion Date

October 31, 2015

Study Completion Date

October 31, 2015

Conditions
Heart Failure
Interventions
DRUG

Fursemide Injection Solution for subcutaneous administration (80 mg)

Furosemide Injection Solution, 10mL of undiluted buffered furosemide solution (8mg/mL)

DRUG

Furosemide Injection, USP

Furosemide Injection, USP (10mg/mL), 80 mg by intravenous administration.

Trial Locations (1)

32720

Avail Clinical Research, LLC, DeLand

All Listed Sponsors
lead

scPharmaceuticals, Inc.

INDUSTRY

NCT02329834 - Crossover Study to Compare the Pharmacokinetics and Bioavailability of a Novel Furosemide Regimen Administered Subcutaneously vs. the Same Dose Administered Intravenously in Subjects With Chronic Heart Failure | Biotech Hunter | Biotech Hunter